O
PALI icon

OrbiMed’s Palisade Bio PALI Stock Holding History

OrbiMed’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.08M Buy
2,333,000
+461,580
+25% +$839K 0.08% 97
2025
Q4 		$4.4M Buy
+1,871,420
New +$3.6M 0.09% 93

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

OrbiMed's PALI Position: Q1 2026 in Review

OrbiMed increased its Palisade Bio (PALI) stake by 25% in Q1 2026, buying an estimated $839K and bringing the position to 2,333,000 shares worth $4.08M. The position accounts for 0.08% of the portfolio, ranked #97.

OrbiMed first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.4M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • OrbiMed held 2,333,000 shares of Palisade Bio worth $4.08M as of Q1 2026.
  • OrbiMed bought 461,580 Palisade Bio shares in Q1 2026, an estimated $839K.
  • Palisade Bio made up 0.08% of OrbiMed's portfolio in Q1 2026, its #97 holding.
  • OrbiMed first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • OrbiMed's Palisade Bio position peaked at $4.4M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.